Please go to the PowerPak homepage
and select a course.
New Therapeutic Options for Multiple Sclerosis: An Update for Specialty and Managed Care Pharmacy
This activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Sandoz.
Fran M. Gengo, PharmD
Associate Professor of Pharmacy and Neurology
The State University of New York (SUNY)
University at Buffalo
Amherst, New York
Michelle M. Rainka, PharmD
Western NY Alzheimer's Association Board of Directors
Dent Neurologic Institute
Amherst, New York
Fran M. Gengo, PharmD, has indicated the following relevant affiliations or financial relationships with a commercial interest: consultant for Dent Neurologic Institute; clinical investigator for Dent Family Foundation, Biogen, Novartis Pharmaceuticals Corporation, and Genentech, Inc./Hoffmann-La Roche Inc.
Michelle Rainka, PharmD, CCRP, has indicated the following relevant affiliations or financial relationships with a commercial interest: clinical investigator for Biogen, Novartis Pharmaceuticals Corporation, and Hoffmann-La Roche Inc.
The following reviewer, Lee A. Kral, PharmD, hereby states that she does not have any financial relationships or relationships to products or devices with a commercial interest related to the content of this activity.
Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 2.0 hours (0.20 ceu)
Published: December 18, 2015
Expires: December 31, 2017
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes
This accredited activity has been designed for pharmacists and pharmacy technicians.
HOW TO EARN CREDIT
During the period December 18, 2015 through December 31, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To inform and educate pharmacists in all practice settings about currently available multiple sclerosis (MS) medications, including the current and future availability of generic formulations, which may decrease cost and increase medication adherence. Basic information about each of the available therapies, including mechanism of action, U.S. Food and Drug Administration (FDA)-approval for specific types of MS, dosage and administration, adverse effects, and drug interactions will be discussed.
Upon completion of this activity, participants should be better able to:
- Describe the pathophysiology and disease characteristic/types of multiple sclerosis (MS);
- Identify medications that are U.S. Food and Drug Administration (FDA)-approved for all types of MS;
- Discuss basic characteristics of currently available MS medications, including mechanism of action, dosage and administration, adverse effects, and drug interactions;
- Describe the relationship between medication adherence and MS disease control, and potential strategies for overcoming barriers to adherence; and
- Describe the approval pathway for current and future non-innovator MS medications and discuss effective methods to counsel patients about disease management and adherence.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5
DISCLOSURE OF UNLABELED USE AND DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Sandoz. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.